Navigation Links
Study Shows Plasma-Derived Human Thrombin Equivalent to Bovine Thrombin in Achieving Hemostasis in Surgery

Results presented at the 6th Annual Meeting of the Society for the

Advancement of Blood Management (SABM). Separate study presented at SABM finds EVICEL* Fibrin Sealant (Human) more effective than manual compression in achieving hemostasis in vascular


SOMERVILLE, N.J., Sept. 11 /PRNewswire/ -- A randomized study comparing treatment with plasma-derived human thrombin and thrombin derived from bovine sources shows that human thrombin is as effective as bovine thrombin in achieving hemostasis in patients at three-, six- and 10-minute intervals. The study of 305 patients with mild or moderate bleeding during elective cardiovascular, neurological or general surgical procedures also showed that human thrombin was less likely to result in an immune response in patients as compared to bovine thrombin. Study results were presented Friday at the Society for the Advancement of Blood Management meeting in Los Angeles. The study was supported by ETHICON, Inc.

In the study, the proportion of patients achieving hemostasis at 10 minutes (primary outcome) was 97.4% following treatment with human thrombin and also following treatment with bovine-derived thrombin. The percentages of patients achieving hemostasis at six minutes and three minutes were also equivalent. There were no statistically significant differences in several other variables including laboratory assessments, vital signs, blood loss, blood transfusions, time in specialty-care unit, procedure duration, and length of hospital stay.

On August 27, the U.S. FDA approved EVITHROM* Thrombin, Topical (Human) for use in cardiovascular, neurological and general surgery. EVITHROM* was developed in collaboration with OMRIX Biopharmaceuticals, Inc. ETHICON plans to make the product commercially available in the United States in Q4 2007.

"With EVITHROM*, the first plasma-derived human thrombin, surgeons have a new option for hemostasis that is as effective as bovine-derived thrombin but that also reduces the risks of antibody formation associated with the use of thrombin derived from bovine sources," said Cataldo Doria, M.D., Thomas Jefferson University Hospital. Dr. Doria was lead author of the study.

According to the study results, plasma-derived human thrombin and bovine thrombin have similar adverse event profiles. However, more patients who received bovine thrombin demonstrated seroconversion for at least one of the four antibodies assayed than did patients who received human thrombin (12.7% versus 3.3%, respectively).

Results from a separate second study were also presented at the SABM meeting. This study compared the safety and effectiveness of EVICEL* Fibrin Sealant (Human), which contains the same human thrombin as in EVITHROM*, to manual compression (MC) in achieving hemostasis in vascular surgery. In the study, a higher percentage of patients who received EVICEL* achieved hemostasis at four-, seven- and 10-minute time points than patients who received MC. In addition, a lower incidence of treatment failures was observed in the fibrin sealant group. The results of this study suggest that EVICEL* is useful for achieving rapid hemostasis for indicated procedures while introducing no new safety concerns. EVICEL* consists of human plasma-derived thrombin and fibrinogen and is currently the only aprotinin-free fibrin sealant commercially available in the U.S.

EVITHROM* and EVICEL* are contraindicated in individuals known to have anaphylactic or severe systemic reaction to human blood products. As with all plasma-derived products, the risk of transmitting infectious agents cannot be completely eliminated. EVITHROM* and EVICEL* should not be injected directly into the circulatory system or used for the treatment of severe or brisk arterial bleeding. There is a potential risk of thrombosis if EVITHROM* is absorbed systemically.

About ETHICON, Inc.

ETHICON, Inc., a Johnson & Johnson company, is a global medical device company that develops and markets surgical products for use in general surgery, wound management and women's health & urology. Johnson & Johnson Wound Management, a division of ETHICON, offers a complete portfolio of topical and advanced hemostatic products including SURGICEL* Absorbable Hemostat, SURGIFOAM* Absorbable Gelatin Sponge, EVICEL* Fibrin Sealant (Human), and SURGIFLO* Hemostatic Matrix with FlexTip. For more information about ETHICON, please visit .


Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
(Date:11/29/2015)... , Nov. 29, 2015 CIVCO ... guidance technology at the Radiological Society of ... Chicago November 29 – ... is designed to offer customers unrivaled versatility, enhanced ... --> ...
(Date:11/27/2015)... November 27, 2015 Ein ... fortgeschrittenem Krebs.   --> Ein neuer ... Krebs.   --> Ein neuer ... Krebs.   Clinical Cancer Research ... Clinical Cancer Research vom 6. November 2015 ...
(Date:11/26/2015)... , November 27, 2015 ... --> --> ... emergency response system (PERS) market ... for 5 years with APAC ... expected to see a high ...
Breaking Medicine Technology:
(Date:11/28/2015)... ... November 28, 2015 , ... Pixel Film Studios is back again ... choose from, the possibilities are endless. Users have full control over angle of view, ... masking effects, users are sure to get heads to turn. , ProPanel: Pulse offers ...
(Date:11/27/2015)... ... November 27, 2015 , ... ... care in America. As people age, more care is needed, especially with Alzheimer’s, ... and medical professionals are being overworked. The forgotten part of this equation: 80 ...
(Date:11/27/2015)... ... November 27, 2015 , ... ... edition of USA Today in Atlanta, Dallas, New York, Minneapolis, South Florida, with ... digital component is distributed nationally, through a vast social media strategy and across ...
(Date:11/27/2015)... ... ... A simply groundbreaking television series, "Voices in America", which is hosted by ... of issues that are presently affecting Americans. Dedicated to providing the world with a ... the subjects consumers focus on, one episode at a time. , In the ...
(Date:11/27/2015)... CA (PRWEB) , ... November 27, 2015 , ... ... California Medical Associates, Inc. and Dr. Tucker Bierbaum with Emergency Medicine at ... They observed that both STEMI and Sepsis conditions present in similar ways and require ...
Breaking Medicine News(10 mins):